Find comprehensive information on Adenoid Cystic Carcinoma (ACC), also known as Cylindroma. This resource covers ACC diagnosis, clinical documentation, and medical coding, including ICD-10 codes and SNOMED CT terms. Learn about Adenoid Cystic Carcinoma symptoms, treatment options, and prognosis. Ideal for healthcare professionals, medical coders, and patients seeking information on ACC.
Also known as
Malignant neoplasm of accessory sinuses
Covers adenoid cystic carcinoma in sinuses.
Malignant neoplasm of floor of mouth
Includes ACC if originating in the floor of mouth.
Malignant neoplasm of other parts of lip
May include adenoid cystic carcinoma affecting the lip.
Malignant neoplasm of larynx
Includes ACC if found in the larynx.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the Adenoid Cystic Carcinoma primary?
When to use each related code
| Description |
|---|
| Rare malignant tumor of glands, slow-growing but can spread. |
| Benign salivary gland tumor, mostly in parotid gland, well-defined. |
| Malignant salivary gland tumor, often mucoepidermoid or adenoid cystic. |
ACC has varied histology, potentially leading to inaccurate SNOMED CT or ICD-O-3 coding if not precisely documented.
Adenoid cystic carcinoma can occur in various sites. Lack of clear documentation of primary site impacts accurate coding and staging.
ACC's propensity for perineural invasion must be documented for accurate coding, reflecting the complexity and guiding treatment.
Q: What are the key differentiating histopathological features of adenoid cystic carcinoma (ACC) that help distinguish it from other salivary gland tumors?
A: Adenoid cystic carcinoma (ACC), also known as cylindroma, exhibits distinctive histopathological features crucial for accurate diagnosis and differentiation from other salivary gland tumors. Cribriform, tubular, and solid patterns are characteristic, with the cribriform pattern often described as 'Swiss cheese' due to the presence of pseudocysts containing basophilic mucinous or hyaline material. Tubular patterns display duct-like structures lined by epithelial cells, while solid patterns show densely packed basaloid cells. Perineural invasion, a hallmark of ACC, is frequently observed and contributes to its propensity for local recurrence. Immunohistochemical staining can aid diagnosis, with ACC typically expressing markers like c-Kit (CD117), p63, and cytokeratins. Distinguishing ACC from polymorphous low-grade adenocarcinoma (PLGA) and basal cell adenocarcinoma can be challenging, requiring careful assessment of growth patterns, perineural invasion, and immunohistochemical profiles. Explore how these histopathological characteristics are used in conjunction with clinical presentation and imaging findings to achieve a definitive diagnosis of adenoid cystic carcinoma.
Q: How does the perineural spread of adenoid cystic carcinoma (ACC) influence treatment strategies and long-term prognosis for patients?
A: The propensity for perineural spread is a defining characteristic of adenoid cystic carcinoma (ACC) and significantly impacts both treatment strategies and long-term prognosis. ACC cells invade nerves, often extending beyond the grossly visible tumor margins. This subclinical spread makes complete surgical resection challenging, increasing the risk of local recurrence even after seemingly successful surgery. Postoperative radiotherapy, particularly intensity-modulated radiation therapy (IMRT), is often recommended to address microscopic perineural invasion and improve local control. The extent of perineural invasion also influences prognosis, with more extensive involvement associated with a worse outcome. Patients with perineural spread are at higher risk for distant metastasis, although hematogenous spread is less common than perineural dissemination. Consider implementing strategies to meticulously assess perineural invasion during diagnostic workup, including dedicated imaging and histopathological evaluation, to tailor treatment plans and provide accurate prognostic information to patients.
Patient presents with symptoms suggestive of adenoid cystic carcinoma (ACC), also known as cylindroma. Chief complaint includes [Insert chief complaint, e.g., persistent nasal obstruction, facial pain, or bloody nasal discharge]. Physical examination reveals [Insert specific physical findings, e.g., palpable mass in the nasal cavity, parotid gland enlargement, or cranial nerve deficits]. Differential diagnosis includes pleomorphic adenoma, basal cell adenocarcinoma, and squamous cell carcinoma. Given the clinical presentation and concerning for malignancy, further diagnostic workup is indicated. Imaging studies, including CT scan and MRI, were ordered to evaluate the extent of the lesion and potential perineural spread, a hallmark feature of adenoid cystic carcinoma. Biopsy is scheduled to confirm the diagnosis histologically. Histopathology will assess for the characteristic cribriform, tubular, and solid growth patterns of ACC. The TNM staging system will be used to classify the disease following confirmation of the diagnosis. Treatment plan will be determined based on the stage and location of the tumor and may include surgical resection, radiation therapy, or a combination thereof. Patient education regarding adenoid cystic carcinoma prognosis, treatment options, and potential complications was provided. Referral to a head and neck surgeon and radiation oncologist is made for multidisciplinary management. Follow-up appointment scheduled for [Date] to review biopsy results and discuss definitive treatment strategy. ICD-10 code C33 (malignant neoplasm of nasal cavity and middle ear) or C04 (malignant neoplasm of the lip) depending on location, as well as relevant CPT codes for the evaluation and management, imaging studies, and biopsy procedure are recorded for medical billing and coding purposes. Adenoid cystic carcinoma treatment, management, and surveillance are documented in the electronic health record.